Skip to main content

Table 3 IL-33 Baseline characteristics of patients with lung tissue analysis

From: Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease

Characteristics

Never smoker

Smoker

GOLD 1

GOLD 2

P value

(n = 11)

(n = 9)

(n = 8)

(n = 10)

Age (years)

65.5 ± 8.6

57.9 ± 8.9

63.1 ± 7.5

66.9 ± 5.6

0.08

Male

2 (18.2%)

8 (88.9%)

8 (100.0%)

10 (100.0%)

< 0.01

Smoking status

     

 Current smoker

0 (0.0%)

2 (22.2%)

1 (12.5%)

3 (30.0%)

< 0.01

 Ex-smoker

0 (0.0%)

7 (77.8%)

7 (87.5%)

7 (70.0%)

 Pack years

0.0 ± 0.0

37.9 ± 35.7

31.0 ± 15.1

42.1 ± 22.9

< 0.01

PFT

     

 Post BD FVC (L)

2.48 ± 0.4

3.72 ± 0.9

4.30 ± 0.5

3.59 ± 0.7

< 0.01

 Post BD FVC (%)

85.6 ± 10.4

84.9 ± 18.2

100.4 ± 7.4

84.6 ± 10.0

0.03

 Post BD FEV1 (L)

2.00 ± 0.4

3.01 ± 0.6

2.76 ± 0.3

2.10 ± 0.3

< 0.01

 Post BD FEV1 (%)

91.8 ± 14.3

91.2 ± 14.7

87.8 ± 4.7

69.2 ± 8.1

< 0.01

 Post BD FEV1/FVC (%)

80.6 ± 6.9

82.0 ± 6.6

64.1 ± 4.9

59.6 ± 10.0

 < 0.01

 RV (%)

102.9 ± 26.5

100.3 ± 30.1

113.1 ± 18.0

121.4 ± 25.6

0.32

IL-33 stain (%)

17.2 ± 9.4

18.5 ± 8.4

24.4 ± 10.9

34.0 ± 12.6

< 0.01

  1. Data are expressed as mean ± SD or No. (%)
  2. GOLD, global initiative for chronic lung disease; PFT, pulmonary function test; BD, bronchodilator; FVC, forced viral capacity; FEV1, forced expiratory volume in 1 s, RV, residual volume; IL, interleukin